American Society of Hematology

Figure 5

$Figure 5. Engraftment of cord blood fraction by intravenous and intrabone marrow routes. (A) Human engraftment kinetics produced by 2400 CB Lin−CD34+CD38− (+/−; ■) and 48 000 Lin−CD34+CD38+ (+/+; □) cells, respectively, when administrated intravenously (I.V.) into NOD/SCID−β2−/− mice. (B) Although similar doses of +/+ cells were able to engraft in immunodeficient mice at 9 to 12 weeks using intrabone marrow injection (I.B.), the level of engraftment produced was still lower compared with 600+/− cells (♦).$

Engraftment of cord blood fraction by intravenous and intrabone marrow routes. (A) Human engraftment kinetics produced by 2400 CB Lin⁻CD34⁺CD38⁻ (+/−; ■) and 48 000 Lin⁻CD34⁺CD38⁺ (+/+; □) cells, respectively, when administrated intravenously (I.V.) into NOD/SCID⁻β2^−/− mice. (B) Although similar doses of +/+ cells were able to engraft in immunodeficient mice at 9 to 12 weeks using intrabone marrow injection (I.B.), the level of engraftment produced was still lower compared with 600+/− cells (♦).

This Feature Is Available To Subscribers Only